AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy.

ABSTRACT:

Background

An unexpected recurrence of hepatocellular carcinoma (HCC) sometimes occurs in patients with hepatitis C virus (HCV) after treatment with direct-acting antivirals (DAAs). However, the characteristics of patients with HCC recurrence may differ depending on time after DAA treatment. We aimed to identify risk factors related to HCC recurrence according to time after DAA treatment.

Methods

Of 1663 patients with HCV treated with a DAA, 199 patients had a previous history of HCC. We defined HCC recurrence within 1 year after DAA treatment as 'early recurrence', and recurrence more than 1 year after as 'late recurrence'. The different risk factors between the early and late phases of HCC recurrence after the end of DAA therapy were investigated.

Results

Ninety-sev

SUBMITTER: Watanabe T 

PROVIDER: S-EPMC8201700 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature